Successful Response of Oral Etoposide for Refractory Neuroblastoma.
- Author:
Young Myoung KIM
1
;
Bong Jin KIM
;
Jung Pyo KIM
;
Young Ho LEE
Author Information
1. Department of Pediatrics, Dong-A University College of Medicine, Busan, Korea. yhlee1@mail.donga.ac.kr
- Publication Type:Case Report
- Keywords:
Neuroblastoma;
Oral etoposide
- MeSH:
Administration, Oral;
Bone Marrow;
Drug Therapy;
Etoposide*;
Neuroblastoma*;
Salvage Therapy;
Stem Cells
- From:Korean Journal of Pediatric Hematology-Oncology
2003;10(1):115-120
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Intensive chemotherapy with or without stem cell rescue has become widely accepted for treatment of neuroblastoma because increased dose-intensity correlates with improved response rates. For neuroblastoma that is resistant to intensive chemotherapy, further use of high-dose therapy is unlikely to be beneficial. For disease that recurs after myeloablative consolidation, high-dose salvage therapy may not be feasible because of poor bone marrow reserve and may not be justified in view of its morbidity in the absence of a realistic chance for cure. One treatment option in these difficult clinical settings is chronic oral administration of low-dose etoposide. However, there has been a few clinical reports for the experience of oral etoposide for refractory neuroblastoma. We now present 2 cases of successful response of oral etoposide for refractory neuroblastoma.
